Share this article
Share this article
ALBANY, N.Y., May 10, 2021 /PRNewswire/ The genetic testing services market is expected to gain a considerable share across the forecast period of 2019-2027 on the back of the rising use across various applications such as obstetrics, oncology, ancestry, and others. Individuals are being made aware of the importance of early disease diagnosis, which is boosting the growth prospects of the genetic testing services market. Early diagnosis helps in minimizing the severity of the disease and leads to reduced mortality, which proves beneficial for the patients.
Genetic testing services comprise a wide range of laboratory tests undertaken to identify the chromosomes, DNA, proteins, RNA, cytogenic, biochemical, or molecular methods. The advantages related to genetic testing will bring immense growth opportunities during the forecast period.
Data Bridge Market Research has announced the Latest edition of Cancer Diagnostics Market Report 2021 Opportunities, Recent Acquisitions, Strategies and Forecasts 2027”. This Cancer Diagnostics Market report is also all-embracing of the data which covers market definition, classifications, applications, engagements, market drivers & market restraints that are based on the SWOT analysis. This Market report is a comprehensive study about the market which tells about the market status. This report covers key player’s strategies that mainly consist of new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others that advance their footprints in the industry. It also informs about the trending innovation and business policies. Cancer Diagnostics market research report that conducts industry analysis on products, markets, companies, industries and many countries internationally. The market type, size of the organization, availability on-premises a
Data Bridge Market Research has announced the Latest edition of Europe Cancer Diagnostics Market Report 2021 Opportunities, Recent Acquisitions, Strategies and Forecasts 2027”. This Europe Cancer Diagnostics Market report is also all-embracing of the data which covers market definition, classifications, applications, engagements, market drivers & market restraints that are based on the SWOT analysis. This Market report is a comprehensive study about the market which tells about the market status. This report covers key player’s strategies that mainly consist of new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others that advance their footprints in the industry. It also informs about the trending innovation and business policies. Europe Cancer Diagnostics market research report that conducts industry analysis on products, markets, companies, industries and many countries internationally. The market type, size of the organization, avail
E-Mail
IMAGE: Dr. O Dwyer is co-leading the largest precision medicine cancer clinical trial to date, NCI-MATCH, with 39 single-arm phase II treatment arms. Researchers are locating patients for the 12 remaining arms. view more
Credit: University of Pennsylvania
The NCI-Molecular Analysis for Therapy Choice (NCI-MATCH) cancer clinical trial is expanding with the opening of a new treatment arm. The addition, Arm Z1M, is a single-arm phase II study of a two-drug combination, relatlimab and nivolumab, both immunotherapies. To be eligible, patients must have mismatch repair deficiency on genomic testing and tumors that express the
LAG-3 protein, a cancer immunotherapy target. The cancer must also have progressed on anti-PD-1/PD-L1 immunotherapy. The addition brings the number of available treatment arms in NCI-MATCH to 12. The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and the National Cancer Institute (NCI), part of the National Institutes of Health, are co-leading
Share this article
Share this article
ResearchAndMarkets.com s offering.
This report highlights that the market is projected to reach $40.6 billion by 2030. The study also highlights that the market is set to witness a CAGR of 6.09% during the period 2020-2030.
The market is driven by the need for the development of an advanced solution based on various technologies such as next-generation sequencing, in-situ hybridization, and polymerase chain reaction for cancer research in various applications such as diagnosis, prognosis, and treatment.
The market is favored by the development of high-throughput, rapid, sensitive, and multi-parametric solutions for prognosis, diagnostics, and treatment. The gradual increase in the prevalence of cancer globally has furthered the solid tumor testing market.